Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.

Lagassé HAD, Hengel H, Golding B, Sauna ZE.

AAPS J. 2019 May 6;21(4):62. doi: 10.1208/s12248-019-0336-8.

PMID:
31062128
2.

Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Jankowski W, Park Y, McGill J, Maraskovsky E, Hofmann M, Diego VP, Luu BW, Howard TE, Kellerman R, Key NS, Sauna ZE.

Blood Adv. 2019 May 14;3(9):1429-1440. doi: 10.1182/bloodadvances.2018030452.

3.

Translational and transcriptional responses in human primary hepatocytes under hypoxia.

Hettiarachchi GK, Katneni UK, Hunt RC, Kames JM, Athey JC, Bar H, Sauna ZE, McGill JR, Ibla JC, Kimchi-Sarfaty C.

Am J Physiol Gastrointest Liver Physiol. 2019 Jun 1;316(6):G720-G734. doi: 10.1152/ajpgi.00331.2018. Epub 2019 Mar 28.

PMID:
30920299
4.

Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population.

Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE.

Mol Ther Methods Clin Dev. 2018 Jun 15;10:105-112. doi: 10.1016/j.omtm.2018.06.006. eCollection 2018 Sep 21.

5.

Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.

Sauna ZE, Lagassé D, Pedras-Vasconcelos J, Golding B, Rosenberg AS.

Trends Biotechnol. 2018 Oct;36(10):1068-1084. doi: 10.1016/j.tibtech.2018.05.008. Epub 2018 Jun 13. Review.

PMID:
29908714
6.

Immunogenicity assessment during the development of protein therapeutics.

Rosenberg AS, Sauna ZE.

J Pharm Pharmacol. 2018 May;70(5):584-594. doi: 10.1111/jphp.12810. Epub 2017 Sep 5. Review.

PMID:
28872677
7.

Recent advances in (therapeutic protein) drug development.

Lagassé HA, Alexaki A, Simhadri VL, Katagiri NH, Jankowski W, Sauna ZE, Kimchi-Sarfaty C.

F1000Res. 2017 Feb 7;6:113. doi: 10.12688/f1000research.9970.1. eCollection 2017. Review.

8.

Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.

Levin D, Lagassé HA, Burch E, Strome S, Tan S, Jiang H, Sauna ZE, Golding B.

J Thromb Haemost. 2017 Apr;15(4):721-734. doi: 10.1111/jth.13649. Epub 2017 Mar 2.

9.

Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.

Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjær SB, Pascal V, León IR, Gudme CN, Buus S, Sauna ZE.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag1286. doi: 10.1126/scitranslmed.aag1286.

PMID:
28077675
10.

Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B.

Simhadri VL, Hamasaki-Katagiri N, Lin BC, Hunt R, Jha S, Tseng SC, Wu A, Bentley AA, Zichel R, Lu Q, Zhu L, Freedberg DI, Monroe DM, Sauna ZE, Peters R, Komar AA, Kimchi-Sarfaty C.

J Med Genet. 2017 May;54(5):338-345. doi: 10.1136/jmedgenet-2016-104072. Epub 2016 Dec 22.

11.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

12.

Personalized approaches to the treatment of hemophilia A and B.

Simhadri VL, Banerjee AS, Simon J, Kimchi-Sarfaty C, Sauna ZE.

Per Med. 2015 Aug;12(4):403-415. doi: 10.2217/pme.15.6.

PMID:
29771661
13.

Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene.

Sarachana T, Dahiya N, Simhadri VL, Pandey GS, Saini S, Guelcher C, Guerrera MF, Kimchi-Sarfaty C, Sauna ZE, Atreya CD.

PLoS One. 2015 Jul 15;10(7):e0132433. doi: 10.1371/journal.pone.0132433. eCollection 2015.

14.

Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery.

Hoinka J, Berezhnoy A, Dao P, Sauna ZE, Gilboa E, Przytycka TM.

Nucleic Acids Res. 2015 Jul 13;43(12):5699-707. doi: 10.1093/nar/gkv308. Epub 2015 Apr 13.

15.

AptaCluster - A Method to Cluster HT-SELEX Aptamer Pools and Lessons from its Application.

Hoinka J, Berezhnoy A, Sauna ZE, Gilboa E, Przytycka TM.

Res Comput Mol Biol. 2014;8394:115-128.

16.

Pharmacogenetics and the Immunogenicity of Protein Therapeutics.

Pandey GS, Sauna ZE.

J Interferon Cytokine Res. 2014 Dec;34(12):931-937.

PMID:
25493960
17.

Fc fusion as a platform technology: potential for modulating immunogenicity.

Levin D, Golding B, Strome SE, Sauna ZE.

Trends Biotechnol. 2015 Jan;33(1):27-34. doi: 10.1016/j.tibtech.2014.11.001. Epub 2014 Dec 6. Review.

PMID:
25488117
18.

Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B.

Saini S, Hamasaki-Katagiri N, Pandey GS, Yanover C, Guelcher C, Simhadri VL, Dandekar S, Guerrera MF, Kimchi-Sarfaty C, Sauna ZE.

Haemophilia. 2015 Mar;21(2):210-8. doi: 10.1111/hae.12553. Epub 2014 Dec 2.

PMID:
25470321
19.

The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.

Sauna ZE, Lozier JN, Kasper CK, Yanover C, Nichols T, Howard TE.

Blood. 2015 Jan 8;125(2):223-8. doi: 10.1182/blood-2013-12-530113. Epub 2014 Nov 18. Review.

20.

Exposing synonymous mutations.

Hunt RC, Simhadri VL, Iandoli M, Sauna ZE, Kimchi-Sarfaty C.

Trends Genet. 2014 Jul;30(7):308-21. doi: 10.1016/j.tig.2014.04.006. Epub 2014 Jun 19. Review.

PMID:
24954581
21.

Single-nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF-cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family.

Kim B, Hing ZA, Wu A, Schiller T, Struble EB, Liuwantara D, Kempert PH, Broxham EJ, Edwards NC, Marder VJ, Simhadri VL, Sauna ZE, Howard TE, Kimchi-Sarfaty C.

Br J Haematol. 2014 Apr;165(1):154-8. doi: 10.1111/bjh.12713. Epub 2014 Jan 16. No abstract available.

PMID:
24433405
22.

Building better drugs: developing and regulating engineered therapeutic proteins.

Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE.

Trends Pharmacol Sci. 2013 Oct;34(10):534-48. doi: 10.1016/j.tips.2013.08.005. Epub 2013 Sep 20. Review.

PMID:
24060103
23.

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.

Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, Sauna ZE; PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators.

Nat Med. 2013 Oct;19(10):1318-24. doi: 10.1038/nm.3270. Epub 2013 Sep 15.

24.
25.

Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry.

Pandey GS, Tseng SC, Howard TE, Sauna ZE.

Biomed Res Int. 2013;2013:793502. doi: 10.1155/2013/793502. Epub 2013 Feb 28.

26.

Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).

Hershko K, Simhadri VL, Blaisdell A, Hunt RC, Newell J, Tseng SC, Hershko AY, Choi JW, Sauna ZE, Wu A, Bram RJ, Komar AA, Kimchi-Sarfaty C.

J Biol Chem. 2012 Dec 28;287(53):44361-71. doi: 10.1074/jbc.M112.383968. Epub 2012 Nov 9.

27.

Characterization of coding synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approaches.

Edwards NC, Hing ZA, Perry A, Blaisdell A, Kopelman DB, Fathke R, Plum W, Newell J, Allen CE, S G, Shapiro A, Okunji C, Kosti I, Shomron N, Grigoryan V, Przytycka TM, Sauna ZE, Salari R, Mandel-Gutfreund Y, Komar AA, Kimchi-Sarfaty C.

PLoS One. 2012;7(6):e38864. doi: 10.1371/journal.pone.0038864. Epub 2012 Jun 29.

28.

Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective.

Sauna ZE, Ameri A, Kim B, Yanover C, Viel KR, Rajalingam R, Cole SA, Howard TE.

J Thromb Haemost. 2012 Sep;10(9):1961-5. doi: 10.1111/j.1538-7836.2012.04830.x. No abstract available.

29.

Identification of sequence-structure RNA binding motifs for SELEX-derived aptamers.

Hoinka J, Zotenko E, Friedman A, Sauna ZE, Przytycka TM.

Bioinformatics. 2012 Jun 15;28(12):i215-23. doi: 10.1093/bioinformatics/bts210.

30.

Analysis of F9 point mutations and their correlation to severity of haemophilia B disease.

Hamasaki-Katagiri N, Salari R, Simhadri VL, Tseng SC, Needlman E, Edwards NC, Sauna ZE, Grigoryan V, Komar AA, Przytycka TM, Kimchi-Sarfaty C.

Haemophilia. 2012 Nov;18(6):933-40. doi: 10.1111/j.1365-2516.2012.02848.x. Epub 2012 May 29.

PMID:
22639855
31.

Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins.

Zichel R, Chearwae W, Pandey GS, Golding B, Sauna ZE.

PLoS One. 2012;7(2):e31948. doi: 10.1371/journal.pone.0031948. Epub 2012 Feb 27.

32.

Plasma derivatives: new products and new approaches.

Sauna ZE, Pandey GS, Jain N, Mahmood I, Kimchi-Sarfaty C, Golding B.

Biologicals. 2012 May;40(3):191-5. doi: 10.1016/j.biologicals.2011.11.003. Epub 2012 Jan 11. Review.

PMID:
22239993
33.

Pharmacogenetics and the immunogenicity of protein therapeutics.

Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE.

Nat Biotechnol. 2011 Oct 13;29(10):870-3. doi: 10.1038/nbt.2002. No abstract available.

PMID:
21997623
34.

Understanding the contribution of synonymous mutations to human disease.

Sauna ZE, Kimchi-Sarfaty C.

Nat Rev Genet. 2011 Aug 31;12(10):683-91. doi: 10.1038/nrg3051. Review.

PMID:
21878961
35.

Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites.

Ohnuma S, Chufan E, Nandigama K, Jenkins LM, Durell SR, Appella E, Sauna ZE, Ambudkar SV.

Biochemistry. 2011 May 10;50(18):3724-35. doi: 10.1021/bi200073f. Epub 2011 Apr 13.

36.

The signaling interface of the yeast multidrug transporter Pdr5 adopts a cis conformation, and there are functional overlap and equivalence of the deviant and canonical Q-loop residues.

Ananthaswamy N, Rutledge R, Sauna ZE, Ambudkar SV, Dine E, Nelson E, Xia D, Golin J.

Biochemistry. 2010 Jun 1;49(21):4440-9. doi: 10.1021/bi100394j.

37.

Silent (synonymous) SNPs: should we care about them?

Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C.

Methods Mol Biol. 2009;578:23-39. doi: 10.1007/978-1-60327-411-1_2. Review.

PMID:
19768585
38.

Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Sauna ZE, Okunji C, Hunt RC, Gupta T, Allen CE, Plum E, Blaisdell A, Grigoryan V, Geetha S, Fathke R, Soejima K, Kimchi-Sarfaty C.

PLoS One. 2009 Aug 5;4(8):e6506. doi: 10.1371/journal.pone.0006506.

39.

Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry.

Geetha S, Allen CE, Hunt RC, Plum E, Garfield S, Friedman SL, Soejima K, Sauna ZE, Kimchi-Sarfaty C.

Cytometry A. 2009 Aug;75(8):675-81. doi: 10.1002/cyto.a.20748.

40.

Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5: possible conservation of a signaling interface for coupling ATP hydrolysis to drug transport.

Sauna ZE, Bohn SS, Rutledge R, Dougherty MP, Cronin S, May L, Xia D, Ambudkar SV, Golin J.

J Biol Chem. 2008 Dec 12;283(50):35010-22. doi: 10.1074/jbc.M806446200. Epub 2008 Oct 8.

41.

Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima.

Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Nussinov R.

J Mol Biol. 2008 Nov 7;383(2):281-91. doi: 10.1016/j.jmb.2008.08.012. Epub 2008 Aug 12. Review.

42.

Genomics and the mechanism of P-glycoprotein (ABCB1).

Sauna ZE, Kim IW, Ambudkar SV.

J Bioenerg Biomembr. 2007 Dec;39(5-6):481-7. Review.

PMID:
18058211
43.

Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP.

Sauna ZE, Kim IW, Nandigama K, Kopp S, Chiba P, Ambudkar SV.

Biochemistry. 2007 Dec 4;46(48):13787-99. Epub 2007 Nov 8.

PMID:
17988154
44.

Complete inhibition of the Pdr5p multidrug efflux pump ATPase activity by its transport substrate clotrimazole suggests that GTP as well as ATP may be used as an energy source.

Golin J, Kon ZN, Wu CP, Martello J, Hanson L, Supernavage S, Ambudkar SV, Sauna ZE.

Biochemistry. 2007 Nov 13;46(45):13109-19. Epub 2007 Oct 23.

PMID:
17956128
45.

Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.

Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.

Cancer Res. 2007 Oct 15;67(20):9609-12. Review.

46.
47.

The sounds of silence: synonymous mutations affect function.

Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.

Pharmacogenomics. 2007 Jun;8(6):527-32. No abstract available.

48.
49.

A "silent" polymorphism in the MDR1 gene changes substrate specificity.

Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM.

Science. 2007 Jan 26;315(5811):525-8. Epub 2006 Dec 21. Erratum in: Science. 2011 oCT 7;334(6052):39. Science. 2007 Nov 30;318(5855):1382-3.

50.

Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections.

Sauna ZE, Shukla S, Ambudkar SV.

Mol Biosyst. 2005 Jul;1(2):127-34. Epub 2005 May 26. Review.

PMID:
16880974

Supplemental Content

Loading ...
Support Center